Use of enhanced green fluorescent protein to monitor retroviral-mediated gene therapy in human keratinocytes by Spandau, D.F. (D.) et al.
Exp Dermatol 2000: 9: 252–257 Copyright C Munksgaard 2000
Printed in Denmark ¡ All rights reserved EXPERIMENTAL DERMATOLOGY
ISSN 0906-6705
Use of enhanced green fluorescent protein to
monitor retroviral-mediated gene therapy in
human keratinocytes
Spandau DF, Marques M, Bierhuizen M, Wagemaker G, Hurwitz S, Pei D. F. Spandau1,2, M. Marques1,
Y, Breese R, Travers JB. Use of enhanced green fluorescent protein to M. Bierhuizen5,
monitor retroviral-mediated gene therapy in human keratinocytes. G. Wagemaker5, S. Hurwitz1,
Exp Dermatol 2000: 9: 252–257. C Munksgaard, 2000 Y. Pei1, R. Breese3 and
J. B. Travers1,3,4Abstract: Keratinocytes have great promise as targets for gene therapy
Departments of 1Dermatology, 2Biochemistryinvolving both skin as well as for systemic disorders due to their availability
and Molecular Biology, 3Pediatrics, andand potential long life span. Improvement of gene transfer into keratino- 4Pharmacology, Indiana University School ofcytes will be greatly facilitated by markers that will allow both rapid Medicine Indianapolis, Indiana, USA; 5Institute of
detection and efficient selection of transduced cells. For these purposes, Hematology, Erasmus University Rotterdam,
a recombinant version of the Aequorea victoria green fluorescent protein The Netherlands
that is enhanced for high-level expression in mammalian cells (EGFP)
was placed into a replication-deficient retroviral vector. High-titer retro-
virus was used to transduce both primary cultures of neonatal foreskin-
derived human keratinocytes (HK) as well as the immortalized keratino-
cyte-derived cell line HaCaT. Both cell types stably expressed the EGFP, Key words: keratinocytes – retrovirus – green
and this marker allowed rapid purification of transduced cells by fluor- fluorescent protein – apoptosis
escence-activated cell sorting. EGFP expression was seen in HaCaT kera- Dan F. Spandau, Department of Dermatology,
tinocytes for at least 40 passages, and the presence of this construct did Indiana University School of Medicine,
not effect cell growth, or apoptosis in response to UVB or etoposide. 975 W. Walnut Street, Rm. 349, Indianapolis,
Transduced populations of HK were grafted into SCID mice, resulting in IN 46202–5121 USA
a functional epidermis. EGFP expression was readily seen in vivo by ex- Tel.: 317 274 7115
Fax: 317 278 2815posing the xenografts to an ultraviolet light source. These studies dem-
e-mail: DSPANDA/IUPUI.EDUonstrate the feasibility of using EGFP as a convenient and rapid marker
to monitor keratinocyte gene transfer both in vitro and in vivo. Accepted for publication 25 October 1999
Introduction
The human keratinocyte is a very attractive target
for gene therapy (reviewed in 1, 2). The skin is very
accessible, and keratinocytes can be routinely ex-
panded in vitro. Employing the epidermis for gene
therapy allows constant and instantaneous moni-
toring of the treatment site. This feature could per-
mit easy removal of the genetically modified area
if needed. These safety concerns as well as the
long-lived nature of keratinocytes in vivo have all
served to generate interest in gene therapy target-
ing keratinocytes.
Retroviral vectors are powerful gene transfer ve-
Abbreviations:
E-GFP, enhanced green fluorescent protein; HK, human kera-
tinocyte; UVB, ultraviolet B radiation.
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hicles for the transduction of therapeutic genes
into somatic cells (reviewed by 3, 4). The majority
of retroviral vectors in use are designed to express
2 genes, the gene of interest as well as a dominant
selectable marker. The selectable marker is used to
facilitate the selection of retroviral producer
clones, titration of virus on indicator cells, as well
as to select target cells, which have been success-
fully transduced. Common selectable markers for
retroviruses include genes which encode for en-
zymes which inactivate otherwise toxic levels of
neomycin, hygromycin or puromycin. In addition,
enzymes such as beta-galactosidase that are associ-
ated with a color change when incubated with ap-
propriate substrate have been used as reporter
genes.
Green fluorescent protein from the jellyfish Ae-
quorea victoria have an inherent green biolumin-
GFP as a marker for keratinocyte gene therapy
escence that can be excited optically by blue light
or by nonradiative energy transfer (5, 6). These
qualities have allowed the use of enhanced green
fluorescent protein (EGFP) as a reporter molecule
in the fluorescent localization and trafficking of
various proteins, including membrane-associated
g-protein receptors (7). GFP proteins have been
expressed by retroviruses and are useful in the
monitoring of cell transduction (8).
The high transduction efficiency of retroviral
vectors makes them attractive vehicles for gene
transduction in keratinocytes. Human keratino-
cytes are readily transduced by retroviruses (9, 10).
Transduced keratinocytes have been grafted into
immunodeficient mice. Though the first studies re-
sulted in engraftment of transduced keratinocytes
in vivo for times measured in days to weeks (11,
12), more recent reports have shown long-term en-
graftment measured in months (13). One potential
problem for current xenografting studies is the
lack of a marker, which could be used to monitor
gene therapy in a non-invasive manner.
The objective of these studies was to evaluate the
feasibility of using EGFP as a marker for retrovir-
al-mediated gene transfer into keratinocytes. Using
a replication-deficient Moloney leukemia virus vec-
tor that encodes EGFP, we report the ability to
transduce both primary cultures of human kera-
tinocytes and the keratinocyte-derived immortal-
ized cell line HaCaT (14). Epidermal cells trans-
duced with this retrovirus fluoresced in vitro, as
well as in vivo when grafted into SCID mice. Ex-
pression of this protein did not effect growth nor
result in enhanced susceptibility to apoptosis in re-
sponse to UVB or etoposide. These findings indi-
cate that EGFP can be used to evaluate retroviral-
mediated gene transfer in human keratinocytes.
Materials and methods
Reagents
Routine chemicals were obtained from Sigma (St
Louis, MO, USA). Growth media and supplements
were purchased from Life Technologies (Gaithers-
burg, MD, USA) and fetal bovine serum from In-
tergen (Purchase, NY, USA).
Generation of the MFG-EGFP retroviral producer
cells
A recombinant replication-deficient retroviral vec-
tor was constructed by placing the complete cod-
ing sequence of EGFP (originally derived from
pEGFP-C1 (Clontech Laboratories Inc, Palo Alto,
CA, USA); [8]) under transcriptional control of the
MoMLV LTR in the MFG retroviral backbone.
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Polyclonal cell populations of ecotropic and am-
photropic retroviral producer cell lines (GPpiE86
and GPpienvAm12, respectively) were generated
using this MFG-EGFP plasmid as previously de-
scribed (8). Clones were derived from FACS-se-
lected populations of amphotropic (aMFG-
EGFP) producer lines displaying the brightest
green fluorescence.
Cells
Primary cultures of keratinocytes and fibroblasts
were obtained from foreskin tissue as previously
described (15). These cells were used before the
third passage. The immortalized human keratino-
cyte-derived cell line HaCaT (14) was a kind gift
from Dr Petra Boukamp (German Cancer Re-
search Center, Heidelberg, Germany) and were
cultured as previously reported (16). Proliferation
assays used 2¿104 cells in l ml media plated in
24 well plates. Cells were trypsinized and counted
(Coulter) on a daily basis. Doubling time was de-
fined as the time necessary for the cell population
to increase 100% while in log phase growth.
Infection of keratinocytes with MFG-EGFP
retrovirus
Both primary cultures of HK or HaCaT cells were
transduced with MFG-EGFP retrovirus as pre-
viously described (17). Briefly, 10 cm2 dishes of
cells (60–70% confluent) were incubated with 10 ml
of supernatants from aMFG-EGFP producer lines
along with 8 mg/ml polybrene for 16 h, and re-
peated. Twenty-four h following the second infec-
tion, the cells were then visualized by epifluoresc-
ent microscopy or subjected to flow cytometry
(FACS Scan; Becton Dickinson).
Measurement of apoptosis in HaCaT cells
HaCaT or HaCaT-MFG-EGFP cells were plated
at 8¿105 cells in 10 cm2 dishes for 24 h. Following
washing, the cells were either treated with etopo-
side (Sigma) or UVB irradiation as previously de-
scribed (18). At various times following treatment,
HaCaT cells were harvested and pelleted. Caspase
3 proteolytic activity in cell lysates was measured
using a synthetic fluorogenic substrate (DEVD-
AMC, Alexis Biochemicals, San Diego, CA, USA;
[19]). The cells were suspended in lysis buffer (50
mM PIPES pH 7.0, 50 mM KCl, 5 mM EGTA, 2
mM MgCl2, 1 mM DTT) for 30 min on ice. Fol-
lowing removal of cellular debris by centrifugation,
an aliquot of the cell lysate was added to caspase
3 reaction buffer (100 mM HEPES, pH 7.5, 10%
sucrose, 0.1% CHAPS, 10 mM DTT, 0.1 mg/ml
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BSA, and 50 mM CPP32-AMC substrate) and in-
cubated at 37æC for 1 h. Release of the fluorescent
AMC moiety was measured using a Hitachi F2000
Spectrophotometer (excitation, 380 nm; emission,
460 nm). The fluorescent intensity was converted
to pmoles of AMC by comparison to the fluor-
escent intensity of standards of AMC (7-amino-4-
methylcoumarin; Molecular Probes, Eugene, OR,
USA). The specific activity of caspase 3 in cell lys-
ates was then determined after the total protein
concentration of the cell lysates was measured
(NanoOrange protein Quantification Reagent,
Molecular Probes). Relative activities were deter-
mined by comparing specific activities derived
from UVB or etoposide-treated cell lysates versus
those derived from untreated cell lysates.
Establishment of xenografts
Dispersed keratinocytes were grafted into
NODLtSz/scid/scid (SCID) mice with minor modi-
fications from published protocols (21). Before use
in the grafting protocols, a sample of peripheral
blood was screened by flow cytometry for T-cells.
Animals used in these studies had ∞1% T cells.
Briefly, silicone grafting domes (Renner GMBH,
Germany) were placed on the dorsum of 2–3
month/old mice using 1% avertin as anesthesia. A
suspension of 5¿106 HaCaT or HK-MFG-EGFP
cells mixed with 2.5¿106 primary human foreskin-
derived fibroblasts was placed into the grafting
domes. The grafting domes were gently removed
after 2 weeks, and white petrolatum placed on the
xenografts on a daily basis. Two–three weeks fol-
lowing removal of the grafting domes, the animals
were sacrificed by CO2 asphyxiation, the xenograft
was excised, and sections were either placed in
formalin for hematoxylin and eosin staining, or
snap-frozen in liquid nitrogen in OCT media.
Frozen blocks of tissue were cut into 6 mm sections
and fluorescence visualized with a Nikon Opti-
phot-2 microscope equipped with epifluorescence.
Results
Transduction of keratinocytes with the MFG-
EGFP retrovirus
To assess the potential of EGFP as a marker for
monitoring retroviral-mediated gene transfer and
expression in human keratinocytes, primary cul-
tures of NHKs or the keratinocyte-derived cell line
HaCaT were incubated with supernatants from
aMFG-EGFP. The green fluorescence of transduc-
ed cells was readily seen by epifluorescent micro-
scopy. Sorting of these epidermal cells on the basis
of EGFP expression demonstrated that the trans-
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duced cells displayed a strong green fluorescent sig-
nal, well separated from the EGFP-negative cells.
Analysis of viable transduced cells by FACS re-
vealed EGFP expression in greater than 50% of
HaCaT and NHKs. The longevity of EGFP ex-
pression in HaCaT cells was assessed by subjecting
a clone of HaCaT-EGFP cells at passage 6 and
also passage 40 to FACS analysis (Fig. 1). Though
substantially reduced, the EGFP was present after
40 continuous passages (approximately one year)
in the majority of cells. These studies indicate the
feasibility of detection and longevity of retroviral-
mediated gene expression using EGFP.
Effects of EGFP expression on epidermal function
in vitro
Previous studies have demonstrated that transduc-
tion with MFG-EGFP does not affect the out-
growth or differentiation potential of immature
hematopoietic cells (8). The influence of EGFP ex-
pression on the growth and cytotoxicity of trans-
duced and FACS-sorted (±95% EGFP-positive)
versus untransduced HaCaT keratinocytes was
next evaluated. The spontaneous proliferation of
these two populations of cells were essentially iden-
tical, with doubling times of approximately 18 h
for parental HaCaT and 17 h for HaCaT-MFG-
EGFP. The next studies examined if retroviral in-
corporation into the cellular genome and resultant
EGFP expression can affect cell cytotoxicity.
HaCaT or HaCaT-MFG-EGFP cells were sub-
jected to UVB irradiation (400 J/m2) or treatment
Figure 1. Monitoring E-GFP expression in HaCaT keratino-
cytes transduced with MFG-EGFP retrovirus. Control HaCaT,
or a clone of HaCaT cells transduced with MFG-EGFP were
subjected to flow cytometry at passage 6, or 40.
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Figure 2. Effect of MFG-EGFP construct on apoptosis induced
by UVB or etoposide in HaCaT keratinocytes. HaCaT or a
population of HaCaTMFG-EGFP cells were treated with 400
J/m2 UVB for 6 h or 5 mM etoposide for 24 h. Cells were har-
vested and caspase 3 enzymatic activity was measured as out-
lined in Methods. The data depict the mean induction ∫SD of
caspase 3 enzymatic activity over untreated cells. The results
shown are typical for 3–4 separate experiments using duplicate
samples.
with etoposide (10 mM), and apoptosis assessed by
measurement of caspase 3 activity. We have pre-
viously demonstrated that caspase 3 induction in
epidermal cells correlates well with other methods
for measuring apoptosis (20). As shown in Fig. 2,
equal levels of caspase 3 enzymatic activity were
noted in parental HaCaT cells versus HaCaT-
MFG-EGFP following these diverse cytotoxic
stimuli. Because the maximum level of caspase 3
induction for 400 J/m2 UVB and 10 mM etoposide
in HaCaT keratinocytes were 6 and 24 h, respec-
tively, the caspase 3 levels at these two times are
depicted in Fig. 2.
Morphologic studies indicated equal numbers of
non-viable cells in HaCaT-MFG-EGFP versus
parental HaCaT in response to both UVB and eto-
poside (data not shown). These studies indicate
that retroviral infection with EGFP expression
does not have untoward effects on either cellular
proliferation, nor does it affect the susceptibility of
HaCaT keratinocytes to programmed cell death.
Establishment of SCID/HK xenografts
The study of human keratinocyte biology has his-
torically relied upon the in vitro culture of primary
HK or carcinoma cell lines. More recently, the in-
creased availability of immunodeficient mice has
allowed study of HK in vivo through xenografts.
Several laboratories have demonstrated the ability
to create functional xenografts of human keratino-
cytes genetically manipulated by retroviruses (11–
13). The following studies were designed to assess
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whether EGFP is a suitable marker for HK in vivo.
Following transduction with EGFP, we grafted
populations of primary cultures of HK into SCID
mice. As shown in Fig. 3, these cells formed viable
xenografts exhibiting a histologically normal epi-
dermis when grafted into SCID mice (Fig. 3D).
Green fluorescence was readily visualized in the in-
tact xenografts in vivo by use of an ultraviolet light
source (Fig. 3B). Frozen sections of the xenografts
from cells transduced with EGFP demonstrated
green fluorescence (Fig. 3C). These studies indicate
that EGFP is an appropriate and easily visualized
marker for retroviral-mediated human keratino-
cyte gene therapy in vivo.
Discussion
The accessibility and other features of keratino-
cytes have made these cells promising targets for
gene therapy. Problems in the use of HK in gene
therapy include the need for vectors, which will
provide long-term stable transduction, as well as
the need to direct therapy towards the stem cell
population. In addition, the vector used must not
disrupt normal cellular function nor result in
augmented epidermal damage in response to exo-
genous stressors such as ultraviolet radiation.
These studies have explored the feasibility of
the use of EGFP as a marker for HK both in vi-
tro as well as in vivo. Using a Moloney Leukem-
ia-based recombinant replication-deficient retrovi-
ral vector (MFG), we report that HK and the
Figure 3. Visualization of human keratinocyte-MFG-EGFP
cells. Primary cultures of human keratinocyte were transduced
with MFG-EGFP and sorted by flow cytometry and grafted
into SCID mice as outlined in Methods. a) Epifluorescence of
HKMF-EGFP cells in culture demonstrating green fluor-
escence. b) Epifluorescence of an intact HKMFG-EGFP/SCID
xenograft at 1 month. Sections of the HKMFG-EGFP/SCID
xenograft were taken and directly visualized by epifluorescence
(c) or stained with hematoxylin and eosin (d).
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keratinocyte-derived epidermal cell line HaCaT
are readily transduced at high efficiencies.
Though the EGFP expression decreases over
time, the majority of HaCaT keratinocytes are
still positive for this marker after 1 year in con-
tinuous culture.
Unlike other selectable markers such as neo-
mycin phosphotransferase, cells expressing EGFP
can be rapidly separated from uninfected cells by
means of flow cytometry. Thus, in addition to its
ability to act as a reporter gene, EGFP can act as
a ‘‘selectable marker’’. In contrast to other reporter
genes in common use in keratinocytes such as beta-
galactosidase, EGFP can be easily visualized both
in vitro as well as in vivo without compromising the
transduced cells. The non-invasiveness of EGFP
monitoring would be advantageous, particularly in
in vivo gene therapy protocols. The present studies
examined short-term (4–6 weeks) expression of
GFP-expressing human epidermal xenografts.
However, that other laboratories have reported
that HK transduced with other retroviral vectors
results in stable expression of the transgene in im-
munodeficient mice (13), coupled with our long-
term studies with HaCaTMFG-EGFP cells (Fig.
1) suggest that EGFP-expressing vectors could be
used for long-term use in vivo.
It is important that proteins used as markers for
gene therapy do not have adverse effects upon the
cells, which express them. Growth studies with
HaCaT keratinocytes indicate that the presence of
EGFP does not effect spontaneous proliferation in
this immortalized cell line. In addition, pro-
grammed cell death due to two diverse stimuli was
not affected by the presence of the incorporated
provirus into the genomic DNA, or expression of
the EGFP.
In summary, these studies demonstrate the feasi-
bility of using EGFP as a marker for keratinocyte
gene therapy, both in vitro as well as in vivo. This
protein seems well tolerated by epidermal cells.
Though the present studies use HK xenografts in
an immunosuppressed mouse, the recent develop-
ment of humanized forms of GFP (22) could allow
use of this family of proteins for human gene ther-
apy protocols.
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